Merck & Co in $2.7bn cancer research acquisition
12-12-2019
TAG supports opposition of Sanofi TB drug patents in India
09-12-2019
Keitma / Shutterstock.com
Sanofi is to acquire Synthorx, a biotechnology company focused on improving the lives of people suffering from cancer and autoimmune diseases, for $2.5 billion.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Sanofi, Synthorx, biotechnology, cancer, autoimmune diseases, acquisition, diabetes, Paul Hudson, therapeutics
